KRAS mutations in endometrial cancers: Possible prognostic and treatment implications

Patients with recurrent or metastatic endometrial cancer (EC) have poor prognoses with limited therapeutic options following immunotherapy or immunochemotherapy treatments. Inhibitors of KRAS mutations (KRAS-mut) have shown efficacy in early solid tumor studies, but data in EC are lacking. This stud...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Gynecologic oncology 2024-12, Vol.191, p.299-306
Hauptverfasser:	Kilowski, Karolina A., Dietrich, Martin F., Xiu, Joanne, Baca, Yasmine, Hinton, Andrew, Ahmad, Sarfraz, Herzog, Thomas J., Thaker, Premal, Holloway, Robert W.
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged B7-H1 Antigen - antagonists & inhibitors B7-H1 Antigen - genetics Biomarkers, Tumor - genetics BRCA1 Protein - genetics BRCA2 Protein - genetics Endometrial cancer Endometrial Neoplasms - drug therapy Endometrial Neoplasms - genetics Endometrial Neoplasms - immunology Endometrial Neoplasms - pathology Endometrial Neoplasms - therapy Female Humans Immunotherapy Immunotherapy - methods KRAS mutations Microsatellite Instability Middle Aged Mutation Prognosis Proto-Oncogene Proteins p21(ras) - genetics Targeted therapy Tumor mutational burden
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!